ATE423849T1 - Dimer eines aus der c-terminalen sequenz der humanen superoxid dismutase abgeleiteten peptids, welches das eindringen einer substanz in zellen und/oder zellkerne erleichert - Google Patents

Dimer eines aus der c-terminalen sequenz der humanen superoxid dismutase abgeleiteten peptids, welches das eindringen einer substanz in zellen und/oder zellkerne erleichert

Info

Publication number
ATE423849T1
ATE423849T1 AT04292771T AT04292771T ATE423849T1 AT E423849 T1 ATE423849 T1 AT E423849T1 AT 04292771 T AT04292771 T AT 04292771T AT 04292771 T AT04292771 T AT 04292771T AT E423849 T1 ATE423849 T1 AT E423849T1
Authority
AT
Austria
Prior art keywords
cells
vector
substance
cell
penetration
Prior art date
Application number
AT04292771T
Other languages
English (en)
Inventor
Eustrate Avrameas
Therese Ternynck
Original Assignee
Diatos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatos Sa filed Critical Diatos Sa
Application granted granted Critical
Publication of ATE423849T1 publication Critical patent/ATE423849T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
AT04292771T 2000-03-01 2001-03-01 Dimer eines aus der c-terminalen sequenz der humanen superoxid dismutase abgeleiteten peptids, welches das eindringen einer substanz in zellen und/oder zellkerne erleichert ATE423849T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0002621A FR2805821B1 (fr) 2000-03-01 2000-03-01 Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires

Publications (1)

Publication Number Publication Date
ATE423849T1 true ATE423849T1 (de) 2009-03-15

Family

ID=8847589

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01911821T ATE372346T1 (de) 2000-03-01 2001-03-01 Von humanen proteinen, welche mit heparin reagieren, abgeleitete aminosäuresequenzen, die den transfer von substanzen von interesse in das innere von zellen und/oder zellkernen erleichtern
AT04292771T ATE423849T1 (de) 2000-03-01 2001-03-01 Dimer eines aus der c-terminalen sequenz der humanen superoxid dismutase abgeleiteten peptids, welches das eindringen einer substanz in zellen und/oder zellkerne erleichert

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01911821T ATE372346T1 (de) 2000-03-01 2001-03-01 Von humanen proteinen, welche mit heparin reagieren, abgeleitete aminosäuresequenzen, die den transfer von substanzen von interesse in das innere von zellen und/oder zellkernen erleichtern

Country Status (13)

Country Link
EP (2) EP1526183B1 (de)
JP (1) JP4912556B2 (de)
AT (2) ATE372346T1 (de)
AU (1) AU780785B2 (de)
BR (1) BR0108847A (de)
CA (1) CA2401613A1 (de)
DE (2) DE60130324T2 (de)
DK (1) DK1259541T3 (de)
ES (1) ES2292567T3 (de)
FR (1) FR2805821B1 (de)
IL (3) IL151399A0 (de)
PT (1) PT1259541E (de)
WO (1) WO2001064738A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
CA2425610A1 (en) 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
FR2841902A1 (fr) * 2002-07-08 2004-01-09 Diatos Peptides lineaires cationiques ayant des proprietes antibacteriennes et/ou antifongiques
FR2858772A1 (fr) * 2003-08-14 2005-02-18 Diatos Composition anti bacterienne, plus particulierement contre les bacteries gram negatif, comprenant un peptide et un agent anti-bacterien avantageusement hydrophobe
EP1512696A1 (de) * 2003-08-14 2005-03-09 Diatos Aminsäuresequenz, die den Transfer von Substanzen von Interesse in das Innere von Zellen und/oder Zellkernen erleichtern
WO2005016960A2 (en) * 2003-08-14 2005-02-24 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
JP5221368B2 (ja) 2005-11-14 2013-06-26 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） Ｐａｒｐ活性のインヒビター及びその使用
EP1797901A1 (de) 2005-12-16 2007-06-20 Diatos Zelldurchlässige Peptidkonjugate zum Transfer von Nukleinsäuren in Zellen
EP1818395A1 (de) * 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
EP1998809B1 (de) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Konjugate von camptothecin und zelldurchdringenden peptiden und deren pharmazeutische zusammensetzungen.
EP2172209A1 (de) 2008-10-03 2010-04-07 Universite Pierre Et Marie Curie Behandlung von Stimmungs- und Angstzustandstörungen
EP2539445B1 (de) 2010-02-26 2018-03-21 Cellectis Verwendung von endonukleasen für den einsatz von transgenen in safe-harbor-loci
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
WO2012159164A1 (en) * 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
PL2812024T3 (pl) * 2012-02-09 2018-09-28 Var2 Pharmaceuticals Aps Celowanie glikanów siarczanu chondroityny
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
CN112457383B (zh) * 2020-12-16 2022-06-17 阿南达 一种多肽、制备方法及其医药用途
AU2022409717A1 (en) 2021-12-16 2024-05-30 Pags Co., Ltd. Cell penetrating polypeptides (cpps) and their use in human therapy
WO2024261742A1 (en) 2023-06-21 2024-12-26 Nano Ghost Ltd Compositions comprising water insoluble drugs and methods of producing and using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60233099A (ja) * 1984-05-04 1985-11-19 Asahi Chem Ind Co Ltd 新規なペプチド
DK455789D0 (da) * 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
WO1996008274A2 (en) * 1994-09-13 1996-03-21 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
FR2736642B1 (fr) 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules

Also Published As

Publication number Publication date
ES2292567T3 (es) 2008-03-16
FR2805821A1 (fr) 2001-09-07
WO2001064738A2 (fr) 2001-09-07
DE60130324D1 (de) 2007-10-18
EP1526183B1 (de) 2009-02-25
EP1259541B1 (de) 2007-09-05
AU4074801A (en) 2001-09-12
EP1259541A2 (de) 2002-11-27
AU780785B2 (en) 2005-04-14
DE60137801D1 (de) 2009-04-09
FR2805821B1 (fr) 2004-01-16
WO2001064738A3 (fr) 2002-09-06
IL151399A (en) 2008-11-26
CA2401613A1 (fr) 2001-09-07
IL190542A0 (en) 2008-11-03
PT1259541E (pt) 2007-12-17
EP1526183A3 (de) 2005-12-07
DK1259541T3 (da) 2008-01-07
IL151399A0 (en) 2003-04-10
JP2003528596A (ja) 2003-09-30
BR0108847A (pt) 2003-02-18
JP4912556B2 (ja) 2012-04-11
ATE372346T1 (de) 2007-09-15
DE60130324T2 (de) 2008-05-29
EP1526183A2 (de) 2005-04-27

Similar Documents

Publication Publication Date Title
DE60137801D1 (de) Dimer eines aus der C-terminalen Sequenz der humanen Superoxid Dismutase abgeleiteten Peptids, welches das Eindringen einer Substanz in Zellen und/oder Zellkerne erleichert
Chattopadhyay et al. Peptides that anneal to natural collagen in vitro and ex vivo
EP2968679B1 (de) Verbessertes verfahren zur herstellung extrazellulärer matrixzusammensetzungen
ES2740826T3 (es) Péptidos de osteopontina modificados que tienen un dominio RGD inactivado y usos de estos
KR101831887B1 (ko) 발모 촉진 활성 및 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
IL128727A0 (en) Angiogenic factor and use thereof in treating cardiovascular disease
EP3263585A3 (de) Foxm1-peptid und arzneimittel damit
EP2796462B1 (de) Antitumorpeptid und verwendung dafür
KR20170097830A (ko) 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도
JP2019508489A (ja) 発毛促進活性及び／又はメラニン生成促進活性を示すペプチド及びその用途
CA2894160A1 (en) Treating oral lesions using placental extracellular matrix
KR20160136342A (ko) 모발 성장의 억제를 위한 오스테오폰틴 유도체를 포함하는 조성물
JP2008534658A (ja) 顔の皺を減らすおよび／または取り除くためのエンケファリン誘導ペプチドを含む化粧品または皮膚用薬剤組成物
ES2283212B1 (es) Peptidos sinteticos utiles en el tratamiento de la piel y su uso en composiciones cosmeticas o dermofarmaceuticas.
JP2002512018A (ja) マトリックス結合因子
JP5858482B2 (ja) スルビビンを調節する新規の抗加齢ペプチドおよびこれを含む組成物
JP2003517809A (ja) 新規ペプチド
WO2003092598A3 (en) Treatment for pompe disease
PL372492A1 (en) Muteins of placental growth factor type 1, preparation method and application thereof
CN114096265A (zh) 衰老进程抑制剂和包含其的食品或饮品
DE10080849D2 (de) Fragmente des Virus Proteins 2 oder 3 des Polymavirus als Fähren für Wirkstoffe
Łubkowska et al. Synthesis of α-collagen fragments and research of their influence on the degree of hydration of a model of epidermis
JP6912992B2 (ja) 細胞賦活剤
JP2915907B2 (ja) インスリン結合用担体

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties